Atorvastatin-Induced Liver Injury with Rapid Enzyme Elevation: A Case-Report

Background: Statins, particularly atorvastatin, are widely used for managing dyslipidemia and preventing cardiovascular events and stroke.Despite their well-documented efficacy, concerns over statin-induced liver injury (SILI), a subset of drug-induced liver injury (DILI), have appeared.Case: this details the clinical presentation, diagnosis, and management of atorvastatin-induced hepatotoxicity in a 55-year-old female patient following a non-ST elevation myocardial infarction (NSTEMI).After being treated with atorvastatin, our patient developed symptoms indicative of liver damage, confirmed by elevated liver enzymes and hepatocellular injury.Atorvastatin was discontinued, resulting in the normalization of liver function.Due to her high cardiovascular risk, rosuvastatin, an alternative statin with a lower hepatotoxicity profile, was introduced, and regular monitoring showed no further complications.Discussion: This case underscores the importance of balancing the cardiovascular benefits of statins against their potential hepatic risks.Clinicians must closely monitor liver function, especially in high-risk patients, and consider alternative statins when reinitiation is necessary.This report highlights the need for individualized treatment plans to mitigate statin-induced hepatotoxicity, ensuring both patient safety and cardiovascular protection.